Moreover, synergistic administration of atezolizumab (anti-PD-L1 mAb) and bevacizumab (anti-VEGF mAb) in treating unresectable hepatocellular carcinoma, currently approved by FDA, showed better tumor response than single administration, although mild-to-moderate adverse reactions were reported [102]. This evidence concerns the gene CD274 and neoplasm.